Comparing effect of agonist & antagonist drugs of Gonadotropin Releasing Hormone (GnRh) in ovulation stimulation

Comparing effect of agonist & antagonist drugs of GnRh in ovulation stimulation in infertile couples with male factor (abnormalities of sperm production and sperm function and obstructions in the ductal system)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201111058010N1

Enrollment

Registered

2012-02-13

Start date

2010-07-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Infertility. Condition 2: Infertility. Condition 3: infertility. Condition 4: infertility. Male infertility Atrophy of testis Other specified disorders of male genital organs Female infertility associated with male factors

Interventions

Intervention 1: Control group: starting Buserelin from the 21th day of previous cycle, daily 50 units and then it shall be decreased from the third day of cycle daily 20 units starting Gonal-F

continuing the process till formation of at least 2 follicles sized 17-18 cm and several follicles sized 14-16 cm

then injecting HCG. Intervention 2: Intervention group: from the 3rd day of cycle, Gonal-F is applied and from the 8th day injecting Cetrotide ampoule dosage 0.25 mg daily, till reaching the mentioned

then stopping stimuli and injecting HCG ampoule.

Treatment - Drugs

Control group: starting Buserelin from the 21th day of previous cycle, daily 50 units and then it shall be decreased from the third day of cycle daily 20 units starting Gonal-F

then injecting HCG.

Intervention group: from the 3rd day of cycle, Gonal-F is applied and from the 8th day injecting Cetrotide ampoule dosage 0.25 mg daily, till reaching the mentioned size of follicle in agonist group

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 18-40 years old ladies, having no risk factor for infertility, with infertile spouse. Exclusion criteria: none.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Number of dominant follicle. Timepoint: The day in which there are seen at least 2 follicles with the sizes 17-18 cm. Method of measurement: Repeating sonography every 2 days from the date of starting induction till ripping follicle having the foregoing particulars.;Number of eggs in third day of fertilization. Timepoint: Third day of fertilization. Method of measurement: counting.;Number of positive clinical pregnancy. Timepoint: 16 day after embryo transfer. Method of measurement: laboratory.;Number of induction days. Timepoint: From the date of starting till injection of HCG ampoule. Method of measurement: counting.;Cost of drugs. Timepoint: From the date of starting till injection of HCG ampoule. Method of measurement: total drug costs.;Number of punctured ovum. Timepoint: Immediately after puncture. Method of measurement: counting.	—

Measure

Time frame

Number of dominant follicle. Timepoint: The day in which there are seen at least 2 follicles with the sizes 17-18 cm. Method of measurement: Repeating sonography every 2 days from the date of starting induction till ripping follicle having the foregoing particulars.;Number of eggs in third day of fertilization. Timepoint: Third day of fertilization. Method of measurement: counting.;Number of positive clinical pregnancy. Timepoint: 16 day after embryo transfer. Method of measurement: laboratory.;Number of induction days. Timepoint: From the date of starting till injection of HCG ampoule. Method of measurement: counting.;Cost of drugs. Timepoint: From the date of starting till injection of HCG ampoule. Method of measurement: total drug costs.;Number of punctured ovum. Timepoint: Immediately after puncture. Method of measurement: counting.

—

Secondary

Measure	Time frame
Incidence of OHSS. Timepoint: 3-5 day after puncture. Method of measurement: sign- sonography-lab.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Hedayat, M.D.

Hamedan University Of Medical Sciences

maryam.hedayat@umsha.ac.ir , dr_hedayat77@yahoo.com+98 81 1827 7012

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026